Vertex Announces U.S. FDA Approval for Orkambi (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to & lt;24 months

With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time BOSTON--(BUSINESS WIRE)--Sep. 2, 2022-- Vertex Pharmaceuticals...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news